Mitomycin C was administered to 22 patients with metastatic breast cancer, refractory to hormonal therapy and conventional chemotherapy. Treatment was given by intravenous bolus injection at 20 mg/m2 of the drug and repeated at 6-week intervals. The overall response rate was 23 %. Two complete remissions were seen in soft tissue lesions. Leukopenia occurred in 68 % of the patients, thrombocytopenia in 36 %, and anemia in 14 %. One case of cardiotoxicity after previous treatment with adriamycin was observed. We conclude that mitomycin C is an active agent in disseminated breast cancer resistant to hormone therapy and chemotherapy. Combination of mitomycin C with other chemotherapeutic drugs will be tested.
Get full access to this article
View all access options for this article.
References
1.
BakerL.H.: Study of mitomycin C in cervical cancer in the United States. Cancer, 35: 155–162, 1979.
2.
BurakerT., NigroN., ComidineB., VaitkeviciusV.K.: Mitomycin-C, 5-fluorouracil and radiation therapy in squamous (epidermoid) cell carcinoma of the anal canal. In: Mitomycin-C. Current Status and New Development, pp. 183–188. CarterS.K., CrookeS.T. (eds.), Academic Press, New York, 1979.
3.
ButlerT.P., MacdonaldJ.S., SmithF.P., SmithL.F., WoolleyP.V., ScheinP.S.: 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung. Cancer, 43: 1183–1188, 1979.
4.
BuzdarA.U., LeghaS.S., TashimaC.K., HortobagyiG.N., YapH.Y., KrutchikA.N., LunaM.A., BlumenscheinG.R.: Adriamycin and mitomycin C: Possible synergistic cardiotoxicity. Cancer Treat. Rep., 62: 1005–1008, 1978.
5.
BuzdarA.U., TashimaC.K., BlumenscheinG.R., HortobagyiG.N., YapH.Y., KrutchikA.N., BodeyG.P., LivingstonR.B.: Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. Cancer, 41: 329–395, 1978.
6.
CrookeS.T., BradnerW.T.: Mitomycin-C: A review. Cancer Treat. Rev., 3: 121–139, 1976.
7.
De LenaM., BrambillaC., MorabitoA., BonadonnaG.: Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate and 5-fluorouracil for advanced breast cancer. Cancer, 35: 1108–1115, 1975.
8.
FriedmanM.A.: A new combination chemotherapy containing mitomycin-C for metastatic breast cancer. In: Mitomycin-C. Current Status and New Developments. pp. 113–119. CarterS.K., CrookeS.T. (eds.), Academic Press, New York, 1979.
9.
GodfreyT.E.: Mitomycin-C in breast cancer. In: Mitomycin-C. Current Status and New Developments. pp. 91–99. CarterS.K., CrookeS.T. (eds.). Academic Press, New York, 1979.
10.
HumG.J., BogdanD.L., BatemanJ.R.: Phase I-II evaluation of weekly mitomycin-C (NSC-26980) for patients with metastatic GI and breast malignancies. Oncology, 30: 236–243, 1974.
11.
LivingstoneR.B., CarterS.K.: Single Agents in Cancer Chemotherapy. pp. 385–394. IFI/Plenum Press, New York, 1970.
12.
MacdonaldJ.S., WoolleyP.V., SmytheT., VenoW., HothD., ScheinP.S.: 5-Fluorouracil, adriamycin and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer, 44: 42–47, 1979.
13.
MooreG.E., BrossI.D.J., AusmanR., NadlerS., JonesR.Jr., SlackN., RimmA.A.: Effects of mitomycin-C (NSC 26980) in 346 patients with advanced cancer. Cancer Chemother. Rep., 52: 675–684, 1968.
14.
MorganL.R.: Adriamycin and mitomycin-C in advanced breast cancer. In: Mitomycin-C. Current Status and New Developments. pp. 101–111. CarterS.K., CrookeS.T. (eds.), Academic Press, New York, 1979.
15.
PanettiereF.J.: Experience of two treatment schedules in the combination chemotherapy of advanced gastric carcinoma. In: Mitomycin-C. Current Status and New Developments. pp. 145–157. CarterS.K., CrookeS.T. (eds.), Academic Press, New York, 1979.
16.
PouillartP., PalangieT., JouveM., Garcia-GiroltE., Mag-DelenatH.: Cancer du sein métastasés. Efficacité d'une association de VM 26, mitomycine-C et de methotrexate chez des malades résistants à une combinaison de 4 drogues comportant l'adriamycine. Bull. Cancer, 66: 485–490, 1979.
17.
ScheinP.S., MacdonaldJ.S., SmithF.P., HothD.F., WoolleyP.: The FAM (5-fluorouracil, adriamycin, mitomycin-C) and SMF (streptozotocin, mitomycin-C, 5-fluorouracil) chemotherapy regimens. In: Mitomycin-C. Current Status and New Developments. pp. 133–143. CarterS.K., CrookeS.T. (eds.), Academic Press, New York, 1979.
18.
Van OosteronA.T., PowlesT.J., HamersmaE., SmithI.E., EngelsmanE.: A phase II study of mitomycin C in refractory advanced breast cancer. Breast Cancer. Experimental and Clinical Aspects.Mouridsen, and Palshot (Ed.), Pergamon Press, Oxford, U.K. (in press).
19.
YamaguchiT., NakamuraM.: Combination therapy with mitomycin-C, 5-fluorouracil and cytosine arabinoside for nonresectable malignant tumor in man. J. Surg. Oncol., 10: 417–429, 1978.
